Glycan excellence against cancer
About Us

Tacalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany.
We strive to develop novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs).


Alena Horn
Office Manager
Fausto Gomes, PhD
Scientist Cell Biology
Francesco Muraca, PhD
Head of Cell Biology
Gustavo Moreira, PhD
Head of Antibody and Protein Biochemistry
Kajo Wiest
Head of Finance & Administration
Prof. Matthias Ocker, MD
Head of Experimental Medicine
Peter Sondermann, PhD
Wiebke Winkler, PhD
Scientist Antibody Generation

Board of Directors

Dr. Klaus Schollmeier
Chairman of the Board
Dr. Alexander Ehlgen
Boehringer Ingelheim Venture Fund
Dr. Frank Hensel
High-Tech Gründerfonds
Ulrich Mahr
Max-Planck-Innovation GmbH
Dr. Peter Neubeck
Kurma Partners
Tim Brans
Karlheinz Schmeling
Creathor Ventures
Prof. Dr. Peter Seeberger
Max-Planck-Institute for Colloids and Interfaces


Tumor-Associated Carbohydrate Antigens (TACAs)

TACAs are attractive targets for novel immunotherapeutics against human cancers. Many TACAs are expressed during embryonic development but not under physiologic conditions in differentiated tissues. On tumors, in contrast, TACAs show very high expression levels, allowing to bring more therapeutic agents to the cancer cell.


Our pipeline comprises several first-in-class assets targeting different TACAs across multiple solid human cancers.
Assets in our pipeline are amenable to various treatment modalities, including antibody-drug conjugates, T cell engagers and others.


Apr 08 2024, 18:00
TCX-101, a novel antibody-drug conjugate targeting a tumor- associated carbohydrate antigen for the treatment of solid tumors
Download document
Mar 28 2024, 18:00
Tacalyx to present at AACR 2024
TCX-101, a novel antibody-drug conjugate targeting a tumor-associated carbohydrate antigen for the treatment of solid tumors

F. G. Gomes, F. Muraca, G. M. Schmidt Garcia Moreira, K. Rösch, M. Bräutigam, P. Sondermann, M. Ocker

Monday, 8th April, 1:30 - 5:00 PM (PST)
Session PO.ET02.01 - Antibody Drug Conjugates (Section 21)
Poster 3125/ 6
Mar 15 2024, 18:00
AACR Annual Meeting 2024 in San Diego
"This event is a fantastic opportunity for us to showcase our latest advancements and explore partnerships to further elevate our cancer research."

MATTHIAS OCKER Head of Experimental Medicine at Tacalyx

We are a growing team of highly motivated scientists. We endorse the biotech spirit of problem solving and let the best idea win. Being innovative and focused is key to have fast decisions and optimized solutions for our early pipeline.
Located in one of Berlin's prestigious science hubs, we offer a vibrant research environment at the forefront of antibody drug development.

Please follow the link for current job offers.
Unsolicited applications are welcome!


Tacalyx GmbH

Magnusstr. 11
12489 Berlin

Follow Us